Skip to main content
S 4013 116th Congress Senate Commerce Administrative law and regulatory procedures Administrative remedies Banking and financial institutions regulation Cardiovascular and respiratory health Civil actions and liability Competition and antitrust Corporate finance and management Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Federal Trade Commission (FTC) Financial services and investments Health technology, devices, supplies Infectious and parasitic diseases Intellectual property Manufacturing Product development and innovation Public contracts and procurement Research and development Strategic materials and reserves

Pandemic Anti-Monopoly Act

Introduced: June 18, 2020 Introduced by: Warren, Elizabeth Democratic · Massachusetts See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 18, 2020
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Jun 18, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Pandemic Anti-Monopoly Act

This bill places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic.

Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that the transaction will advance critical national security, economic, or public health interests during the emergency.

Further, the bill establishes a legal presumption against a transaction that may pose a risk to the government's ability to respond to the national emergency declared due to COVID-19.

What's happening now June 18, 2020

Read twice and referred to the Committee on Commerce, Science, and Transportation.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Independent 1
I
Sanders, Bernard
Vermont · Jun 18, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4013: Pandemic Anti-Monopoly Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-4013/
MLA
"S. 4013: Pandemic Anti-Monopoly Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-4013/.
Bluebook (legal)
S. 4013, 116th Cong. (2026), https://openamerica.io/bill/116-S-4013/.
Markdown link
[S. 4013: Pandemic Anti-Monopoly Act](https://openamerica.io/bill/116-S-4013/)
Report a problem